Alerta

一种基于不饱和脂肪酸的铁死亡调节纳米粒的制备方法及其应用

Resumen de: CN119909036A

一种基于不饱和脂肪酸的铁死亡调节纳米粒的制备方法，该脂质纳米粒由模型药、单不饱和脂肪酸、不同PEG分子量的磷脂聚乙二醇偶联物复合制成，方法是：将模型药、单不饱和脂肪酸与不同PEG分子量的磷脂聚乙二醇偶联物混合，然后溶解于乙醇中，超声混匀，滴入去离子水中，搅拌、旋蒸，除去甲醇和乙醇，离心，除上清液，干燥，即得；原料丰富，制备方法简单，易生产，产品质量好，性质稳定，能通过将多酚类药物有效递送至胰腺炎症部位，极大提高药物生物利用度以及胰腺炎症靶向能力，抑制胰岛β细胞的铁死亡来发挥治疗糖尿病的作用，是治疗糖尿病和胰腺炎药物上的一大创新，社会和经济效益巨大。

速溶性ナノ粒子組成物及びその製造方法

Resumen de: AU2023260204A1

An instant nanoparticle composition and a preparation method therefor. The composition contains an active ingredient, albumin and a particle stabilizer, and optionally contains a lyoprotectant. The active ingredient has the following characteristics: insoluble or slightly soluble in water, and soluble or easily soluble in specific organic solvents, preferably paclitaxel or docetaxel.

一种基于糖链修饰与相变材料的长效稳定重组RSV疫苗

Resumen de: CN119909163A

本发明涉及生物医药技术领域，公开了一种基于糖链修饰与相变材料的长效稳定重组RSV疫苗，所述疫苗包括以下质量份数的组分：动态糖链修饰的RSV F蛋白：1份；多级相变材料：3～5份，所述多级相变材料由聚乙二醇‑硬脂酸酯和月桂酸‑胆固醇复合物组成，其中聚乙二醇‑硬脂酸酯与月桂酸‑胆固醇的质量比为2～3:1；TLR9激动剂：0.05～0.15份；STING激动剂：0.02～0.08份；两亲性嵌段共聚物PLGA‑PEG‑PLL：0.5～1.5份。本发明解决了传统疫苗易失活、靶向性差及免疫原性不足的问题，适用于病毒性感染疾病的预防与治疗，具备规模化生产的应用潜力。

一种共负载黑色素茶多酚-镁的Janus微球及其制备方法与应用

Resumen de: CN119909021A

本发明公开了一种共负载黑色素茶多酚‑镁的Janus微球及其制备方法与应用，利用茶多酚和镁离子在碱性条件下络合形成纳米颗粒以及利用强碱溶解头发中的角蛋白获得黑色素纳米颗粒，将二者分别与甲基丙烯酰胶原混合配制成溶液作为流动相，以植物油作为分散相溶液，在微流控装置中，双通道流动相同轴共流，分散相流体利用流动剪切力将流动相分散为单分散液滴，液滴在紫外激光照射下固化形成共负载黑色素/茶多酚‑镁的Janus微球。本发明借助微流控技术，实现共负载黑色素/茶多酚‑镁的Janus微球的高均一性制备，可以实现协同抗氧化和抗菌治疗，可应用于各种具有抗氧化和抗菌需求的生物医学应用，如促进糖尿病创面、细菌感染性创面等的愈合。

一种RSV抗原、核酸、表达元件、药物组合物及其应用

Resumen de: CN119912537A

本发明公开了一种RSV抗原、核酸、表达元件、药物组合物及其应用。所述RSV抗原为在SEQ ID NO:1的基础上包含突变A102C和S362C。所述RSV抗原具有比现有技术RSV更强的免疫原性，可以取得较高的中和抗体滴度，具有更高的保护效力。

一种抑制卵巢癌的组合物、纳米颗粒、制备方法和应用

Resumen de: CN119909081A

本发明属于纳米医学技术领域，具体涉及一种抑制卵巢癌的组合物、纳米颗粒、制备方法和应用，包括蟾毒它灵和尼拉帕利，所述蟾毒它灵和尼拉帕利的摩尔比为6.25‑12.5:5000‑10000，本发明能够提高卵巢癌的抑制效果。

装载NLRP3-sgRNA核酸序列靶向巨噬细胞的纳米颗粒及防治葡萄膜炎的应用

Resumen de: CN119909039A

本发明提供一种装载NLRP3‑sgRNA核酸序列靶向巨噬细胞的纳米颗粒及防治葡萄膜炎的应用。本发明负载具有特异启动子的NLRP3‑sgRNA质粒，制备纳米颗粒PLGA‑sgNLRP3，然后将巨噬细胞膜包被于PLGA‑sgNLRP3纳米颗粒表面，制备得到巨噬细胞膜包被的纳米颗粒MM/PLGA‑sgNLRP3。本发明能将PLGA‑sgNLRP3和MM/PLGA‑sgNLRP3招募至视网膜病变部位，从而增加药物在病变部位的积蓄，增强基因干预作用，实现高效内毒素诱导的葡萄膜炎病变部位靶向功能，不仅能够减轻视网膜损伤、炎症反应，防止视网膜屏障受损，且具有良好的生物安全性，副作用小，疗效高。

聚合物复合物纳米材料封装系统

Resumen de: AU2023342576A1

Generally, a polymer nanomaterial encapsulation system useful in the production of polymer encapsulated nanoparticles comprised of a hydrophobic nanoparticle encapsulated in the hydrophobic region of the polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanoparticle conjugates. Specifically, particular embodiments include a polymer nanoparticle structure including one or more of: a quantum dot and/or a superparamagnetic iron oxide nanoparticle and/or an upconverting nanoparticle, encapsulated in polystyrene-b-polyethylene glycol amine for the production of antibody conjugates useful in the capture of cellular targets.

一种双穿膜肽修饰的含STING抑制剂特异靶向血管内皮的纳米粒子及其制备方法与应用

Resumen de: CN119909184A

本发明属于生物医药技术领域，具体涉及一种双穿膜肽修饰的含STING抑制剂特异靶向血管内皮的纳米粒子及其制备方法与应用。本发明将STING抑制剂包裹于脂质体中得到脂质体纳米药物，以脂质体作为药物载体能提高其水溶性及生物利用度；同时，利用细胞穿膜肽和靶向穿膜肽共同修饰脂质体纳米药物，两者协同提高穿膜性能，帮助药物穿透眼部屏障，靶向视网膜血管内皮细胞，增加药物的生物利用度。并且，所得纳米粒子是以液态的形式存在，能够直接将其作为滴眼液用于治疗视网膜病变的眼睛，这样便捷、无创的眼部疾病治疗方式，能够更好地造福视网膜疾病患者，减少患者视网膜血管新生，有利于疾病的治疗和预后。

一种纳米自组装体颗粒的制备及用于黑色素瘤靶向成像和光热治疗

Resumen de: CN119909035A

本发明公开了一种用于黑色素瘤靶向成像和光热治疗的自组装纳米颗粒，旨在解决现有光热治疗黑色素瘤方法中靶向性不强、光热效率低以及生物相容性差的问题。本发明设计了一种基于特定多肽(SA‑7)、芳香氨基酸(FF)和卟啉(TPP)的自组装纳米颗粒。通过自组装形成的纳米颗粒能够高效靶向黑色素瘤细胞，在638nm激光照射下产生强效的光热效应。同时，该纳米颗粒具有良好的生物相容性和代谢性能，可用于黑色素瘤的精准成像和治疗。

一种负载胰岛素的复合纳米颗粒及其制备方法和应用

Resumen de: CN119909037A

本发明公开了一种负载胰岛素的复合纳米颗粒及其制备方法和应用，复合纳米颗粒具有核壳结构，核为L‑缬氨酸修饰的壳聚糖与胰岛素自组装形成的聚电解质络合物，壳为阴离子多糖；或者复合纳米颗粒具有多层核壳结构，核为苯硼酸修饰的明胶与胰岛素自组装形成的聚电解质络合物，外面形成两层壳：L‑缬氨酸修饰的壳聚糖、褐藻糖胶。本发明可作糖尿病治疗的口服给药和注射给药。

一种氟代脂质纳米颗粒及其制备方法和应用

Resumen de: CN119912352A

本发明提供了一种氟代脂质体及其制备方法和应用。这一系列结构新颖的高度氟化的可离子化的脂质分子制备方法具有合成简单、产率高的优点。本发明还提供了包含氟代可离子化脂质或复合离子化脂质的LNP，所述LNP粒径分散性好，对于核酸的包封率高，生物体内毒性较低，可以高效的递送核酸药物使其具有更好的进细胞效率、核酸的表达效率，并具有脾脏靶向性，在免疫治疗中具有重大的应用前景。

脂质化合物及其组合物

Resumen de: CN119912351A

本发明涉及一种脂质化合物及其组合物。具体而言，本发明涉及式(I)的脂质化合物，包含其的脂质纳米颗粒，及其制备方法和在药物递送中的用途。#imgabs0#

组合物、成像剂、用于获得数据、提供和开发PDT、开发疗法和材料、评估受试者、MRI成像和升级MRI的方法以及MRI系统

Resumen de: JP2024094323A

To provide innovative drugs, medical products and imaging agents.SOLUTION: Provided is a method of imaging a subject, comprising: (i) administering to the subject an imaging agent having a plurality of nanostructures, each of the nanostructures comprising a multi-armed PEG and one or more additives that interact with the multi-armed PEG, and the multi-armed PEG of each of the plurality of nanostructures is sufficient to provide a nuclear magnetic resonance image when scanned in step (ii); (ii) following step (i), performing an imaging scan of the subject, the imaging scan being a nuclear magnetic resonance scan; and (iii) providing a nuclear magnetic resonance image of the multi-armed PEG of the plurality of nanostructures.

一种蜂皇浆冻干粉的包衣方法及其产品、应用、养肝胶囊及其制备方法

Resumen de: CN119909038A

本发明属于药品技术领域，具体涉及一种蜂皇浆冻干粉的包衣方法及其产品、应用、养肝胶囊及其制备方法。所述蜂皇浆冻干粉的包衣方法，包括以下步骤：S1、将包衣材料溶解于溶剂中，得包衣液：S2、采用包衣液对蜂皇浆冻干粉进行包衣，得包衣蜂皇浆冻干粉；所述包衣材料包括羟丙甲纤维素、改性麦芽糊精和异麦芽酮糖醇。采用本发明提供的包衣蜂皇浆冻干粉制备得到的养肝胶囊在阴凉、常温和加速条件下的水分含量均合格，而且避免了蜂皇浆冻干粉含量的严重下降。

一种用于肺部疾病治疗的纳米颗粒及其制备方法与应用

Resumen de: CN119912435A

本发明公开了一种用于肺部疾病治疗的纳米颗粒及其制备方法与应用。本发明所提供的用于肺部疾病治疗的纳米颗粒包括纳米颗粒载体和核酸分子；所述纳米颗粒载体，其原料包括所述TM2和DOPE，两者的摩尔比为1:2。本发明提供的包载核酸的纳米颗粒能够高效地将核酸分子递送至肺部，下调致病蛋白表达；能够显著增加药物在肺部的沉积，有效保证了给药以后的效果，同时具有给药方式简便，无创伤，安全性高等优点，是一种具有高创新性的高效肺部沉积的一种方式，在肺部相关疾病治疗方面具有很好的应用前景。

柚皮素纳米粒在头孢噻呋长效制剂制备中的应用

Resumen de: CN119424347A

The invention discloses an application of naringenin nanoparticles in preparation of a ceftiofur long-acting preparation. The invention discloses naringenin (5, 7-dihydroxy-2 (4-hydroxyphenyl) chroman-4-ketone), which is a flavonoid substance. The naringenin nanoparticles are prepared, the naringenin nanoparticles are mixed with the ceftiofur for combined use, and it is found that the naringenin can effectively intervene in the pharmacokinetic process of the ceftiofur and significantly prolong the in-vivo half-life period of the ceftiofur, so that the in-vivo action time of the ceftiofur is prolonged, and the curative effect of the ceftiofur is improved. Moreover, the application method is simple, easy to operate, low in cost and suitable for large-scale popularization.

一种抗肿瘤的蜂毒肽组合物及其应用

Resumen de: CN119909158A

本发明涉及蜂毒肽，特别涉及一种抗肿瘤的蜂毒肽组合物及其应用；本发明所述抗肿瘤的蜂毒肽组合物由蜂毒肽和TPGS‑CA通过自组装和静电作用所构成。蜂毒肽与TPGS‑CA形成纳米药物后，首先能够降低蜂毒肽的溶血性，减少其副作用；其次，TPGS‑CA具有较强的负电性，可以逃避网状内皮系统的吞噬延长体内循环时间；最后纳米药物通过EPR效应到达治疗部位后，TPGS‑CA在微酸性环境中能够水解成TPGS和CA，能够进一步加强蜂毒肽的抗肿瘤效果，从而达到高效抗肿瘤的目的。

鞣花酸纳米颗粒在制备具无创深层皮肤药物递送功能的外用制剂中的应用

Resumen de: CN119909061A

本发明提供一种鞣花酸纳米颗粒，无需添加大量辅料与复杂制备工艺，即能解决其溶解度、透皮吸收性能、皮肤深层递送性能极低的问题。将其用于制备具美白、祛斑、抗氧化、抗衰老、清除自由基、祛皱、防晒、增强皮肤的弹性、减少色素沉积、保湿、抗菌、抗病毒、治疗脱发、治疗白发、皮肤去油脂、治疗黑色素瘤、疤痕修复、创面愈合功能中的一种或多种功效的药品、化妆品、日化用品中，显示出向皮肤深层渗透药物的作用，最深可直达及靶向皮肤筋膜层。深层递送性能的提升与溶解度显著增强相关，也与纳米化性质相关，显示鞣花酸纳米颗粒在外用制剂，尤其是皮内深层药物递送的外用制剂的开发前景，这种深层递送不依赖于微针等装置，是完全无创递送的方法。

脳腫瘍への局所療法送達のための組成物及び方法

Resumen de: CN119212744A

Compositions for topical delivery of a drug to an intracranial region, such as brain tissue or brain tumor. Methods for local delivery of drugs or therapies to an intracranial region. The composition may include a hydrogel in which a chemotherapeutic drug or an immunotherapeutic drug is dispersed. Kits comprising a composition or solutions that can be combined to form a composition.

二重特異性ナノ粒子バイオコンジュゲート

Resumen de: AU2023260654A1

The present invention relates to nanoparticle bioconjugates comprising binding proteins for binding to a cancer cell and an antigen of an immune cell, and uses and methods of treatment comprising administration thereof.

二重機能免疫調節化合物、製剤、及びその使用

Resumen de: MX2024013106A

The present disclosure provides dual functioning compounds, compositions, formulations, and methods for inducing or modulating an immune or inflammatory response and treating diseases or disorders (e.g., cancer, autoimmune diseases, inflammatory diseases, and infectious diseases) with the compounds or compositions thereof. In particular disclosed herein are dual functioning compounds comprising a stimulator of interferon (IFN) genes (STING) agonist moiety and a second active moiety selected from an indoleamine 2,3-dioxygenase (IDO) inhibitor and phosphatidylinositol 3â¿`kinase (PI3K) inhibitor, and compositions and formulations thereof.

用于ECT成像和放射增敏治疗的诊疗一体双模态纳米颗粒及其制备方法和用途

Resumen de: CN119909206A

本发明公开一种用于ECT成像和放射增敏治疗的诊疗一体双模态纳米颗粒及其制备方法和用途，属于肿瘤诊疗药物技术领域。所述纳米颗粒由小尺寸铪‑没食子酸纳米颗粒标记可检测标记物得到；所述小尺寸铪‑没食子酸纳米颗粒由聚乙烯吡咯烷酮、四氯化铪与没食子酸通过配位组装形成。本发明提供的双模态纳米颗粒可同时用于ECT成像和放射增敏治疗，具有良好的生物安全性和优异的放疗增敏性能，在体内具有很好的代谢特性，克服常规纳米颗粒会在体内滞留的缺陷。

POLYMER NANOPARTICLE AGGREGATE, METHOD FOR PRODUCING SAME AND USE THEREOF FOR THE TREATMENT OF VENOUS THROMBOSIS

Resumen de: WO2025088242A1

A first aspect of the present invention relates to a nanoparticle aggregate for the treatment of venous thrombosis characterised in that it comprises a combination of negatively charged nanoparticles comprising rtPA and positively charged nanoparticles comprising DNase per nanoparticle. A second aspect of the present invention relates to a method for producing the nanoparticle aggregate. A third aspect of the invention relates to a pharmaceutical composition comprising the nanoparticle aggregate according to the first aspect of the invention. Lastly, the present invention discloses the nanoparticle aggregate for use as a drug and for the treatment of thromboembolic diseases.

LIPID NANOPARTICLE WITH NON-COVALENT BIFUNCTIONAL BINDERS FOR ACTIVE TARGETING

Resumen de: WO2025087303A1

A nanoparticle complex comprises a bifunctional binder capable of non-covalently binding to the lipid nanoparticle in the nanoparticle complex.

IONIZABLE LIPID COMPOUND AND USE THEREOF

Resumen de: WO2025086482A1

Disclosed in the present invention is an ionizable lipid compound and a use thereof. The ionizable lipid compound has a structure as represented by formula (I). In the ionizable lipid compound of the present invention, a polyoxa-structure is introduced in combination with a hydroxyl group at the head, so that the lipid compound has good biocompatibility and excellent in vivo mRNA delivery efficiency. The structural design is novel, the proportion of each component of a matched LNP dosage form is appropriate, and animal experiments have demonstrated that the delivery effect reaches an international advanced level of commercialized ionizable lipids and the safety is good.

NANOPARTICLE COMBINATION THERAPY FOR TUMORS

Resumen de: WO2025088597A1

A method is provided for treating solid tumors in a human body, the method including intravenously administering nanoparticles (32) having a negative zeta potential (ZP) at neutral pH between -5 and -40 mV; and administering chemotherapy drug molecules (34) having a positive ZP at neutral pH or a ZP at neutral pH of between -10 mV and 0 mV. The nanoparticles (32) and the chemotherapy drug molecules (34) are separate from each other until in the human body. The nanoparticles (32) and the chemotherapy drug molecules (34) are administered in respective amounts that are therapeutically effective in combination. The nanoparticles (32) localize on cancer cells of the tumors. The chemotherapy drug molecules (34) are attracted to the nanoparticles (32) in the human body by the opposite charges of the chemotherapy drug molecules (34) and the nanoparticles (32), thereby facilitating localization of the chemotherapy drug molecules (34) on the cancer cells of the tumors. Other embodiments are also described.

JANUS PARTICLES, METHODS AND USES THEREOF

Resumen de: WO2025086003A1

A Janus particle, comprising a particle core, the particle core comprising at least a first surface functionalized with a functional group and a second surface functionalized with a metal particle.

METHOD OF USE OF MESOPOROUS SILICA RODS FOR TREATING CANCER

Resumen de: WO2025090756A2

Embodiments of the invention include methods of treating conditions that are ameliorated by stimulating an immune response. In aspects, the methods include subcutaneous injection of mesoporous silica rods into a subject or patient. The mesoporous silica rods can include a cytokine (e.g., IL-2 or IL-12) and/or an adjuvant. The mesoporous silica structures can induce an innate systemic immune response to treat cancer, infection and other ailments. Embodiments also include methods of producing mesoporous silica rods.

LIPID NANOPARTICLES FORMED BY LIPIDOIDS FOR EFFICIENT DELIVERY OF NUCLEOTIDE DRUGS AND BIOLOGICS

Resumen de: WO2025090612A1

The present technology provides a compound of Formula I, wherein PAO, R and n are defined herein. Also provided are lipid nanoparticles incorporating compounds of Formula I and methods of using same to deliver nucleotide, polynucleic acid or RNP to a cell.

LIPID NANOPARTICLES FOR DELIVERY OF THERAPEUTIC PAYLOADS TO T CELLS

Resumen de: WO2025090525A1

The disclosure provides conjugates comprising a targeting moiety a lipid nanoparticle (LNP) encapsulating a therapeutic agent (e.g., payload) for delivery to immune cells. The conjugates can be delivered to immune cells ex vivo or formulated in a pharmaceutical composition and can be directly administered to a subject in need of (i.e., via in vivo administration).

NANOPARTICLE BASED DELIVERY OF MITOCHONDRIAL DNA (MTDNA) AND METHODS OF USE THEREOF

Resumen de: WO2025090891A1

In some embodiments, the invention relates to a composition for targeted delivery of intact mitochondrial DNA (mtDNA) to a target cell, the composition comprising a mtDNA molecule that is complexed to cell-penetrating peptides (CPPs) which promote cellular entry, wherein the complex forms a nanoparticle with the CPPs bound to the mtDNA molecule. In some embodiments, the invention relates to a method of treating a disease or disorder associated with mitochondrial dysfunction in a subject in need thereof.

SUPERPARAMAGNETIC POLYCRYSTALLINE IRON OXIDE NANOPARTICLES FOR MAGNETIC HYPERTHERMIA

Resumen de: WO2025090766A1

This invention relates to the utilization of superpararmagnetic polycrystalline iron oxide nanoparticles for magnetic hperthermia applications and methods. The present invention provides a magnetic hyperthermia method for treating a condition in a subject, the method comprising: obtaining at least one superparamagnetic nanoparticle, wherein the at least one superparamagnetic nanoparticle comprises a plurality of iron oxide primary crystals, wherein the plurality of iron oxide primary crystals comprise a plurality of crystallites.

METALLIC CATION-MEDIATED ENTRAPMENT OF NUCLEIC ACIDS (MENA) ON MESOPOROUS SILICA SURFACE FOR DELIVERY OF NUCLEIC ACIDS IN BIOLOGICAL ENVIRONMENTS

Resumen de: WO2025090634A1

Compositions comprising a mesoporous silica nanoparticle (MSN) loaded with metal cations and oligonucleotides and methods of use.

COMPOSITIONS AND METHODS FOR TARGETING LIPID NANOPARTICLES

Resumen de: WO2025085950A1

The present invention is directed to lipid-based nanoparticles (e.g. lipid nanoparticles), formulations containing lipid-based nanoparticles and methods of treating diseases or conditions with said lipid-based nanoparticles and formulations thereof. The present invention provides a lipid-based nanoparticle comprising (a) an active agent, and (b) a plurality of capture binding domains displayed on the outer surface of the nanoparticle, wherein each capture binding domain is linked to the lipid-based nanoparticle through a site-specific linkage such that each capture binding domain is displayed in substantially the same orientation and capable of capturing a targeting moiety in an orientation that allows the targeting moiety to interact with its target. The present invention also provides a lipid-based nanoparticle comprising (a) an active agent, and (b) a plurality of targeting molecules displayed on the outer surface of the nanoparticle, wherein each targeting molecule is linked to the lipid-based nanoparticle through a site-specific linkage such that each targeting molecule is displayed in substantially the same orientation and capable of binding to a target on a cell surface.

ABCB5-TARGETED STEM CELL REPROGRAMMING AND ANTI-AGING STRATEGIES

Resumen de: WO2025090565A1

Methods and compositions for rejuvenating and reprogramming stem cells are disclosed. The methods involve administering to a subject an ABCB5 targeted composition comprising an anti-ABCB5 antibody conjugated to a therapeutic payload comprised of an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor in an effective amount to reprogram and rejuvenate ABCB5+ stem cells in the subject. The compositions include anti-ABCB5 antibody conjugated to a therapeutic payload comprising an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor.

STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090422A1

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090138A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, hematopoietic stem cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

NANOPARTICLE COMPOSITION FOR DRUG DELIVERY

Resumen de: WO2025089792A1

The present invention relates to a composition for drug delivery and a preparation method therefor and, more specifically, to: a composition for drug delivery which is formed such that a drug is encapsulated inside a nanoparticle structure formed by a polymer and a cationic lipid having a specific structure; and a preparation method therefor.

IONIZABLE LIPIDS AND USES THEREOF

Resumen de: WO2025089791A1

The present invention relates to a novel ionizable lipid compound represented by Formula (I) or a salt thereof, and a lipid nanoparticle containing the same. The lipid nanoparticle containing the novel ionizable lipid compound according to the present invention has an excellent nucleic acid encapsulation efficiency and has a high efficiency of cellular delivery of nucleic acid.

IONIZABLE LIPID AND USE THEREOF

Resumen de: WO2025089790A1

The present invention relates to a novel ionizable lipid compound represented by formula (I), or a salt thereof, and lipid nanoparticles comprising same. The lipid nanoparticles comprising the novel ionizable lipid compound, according to the present invention, have excellent nucleic acid encapsulation efficiency and high nucleic acid cell delivery efficiency.

NUCLEIC ACID-ENCAPSULATED STABILIZED NANOLIPOSOME CARRIER AND METHOD FOR PRODUCING SAME

Resumen de: WO2025089475A1

The present invention relates to a nucleic acid-encapsulated stabilized nanoliposome carrier and a method for producing same.

ALGA(E) NANOPARTICLES AND USES THEREOF FOR DRUG DELIVERY

Resumen de: WO2025088609A1

Disclosed are biocompatible, biodegradable, and low immunogenic alga(e) Nanoparticles (aNPs) that can adhere and deliver active ingredient(s) to mucosal epithelium tissue, as well as compositions comprising the aNPs, methods of preparing the aNPs, and uses thereof in methods of treatment.

LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME

Resumen de: US2025134824A1

Compositions and methods are provided for stabilization of RNA encapsulated by lipid nanoparticles during lyophilization. The compositions and methods involve the use of empty lipid nanoparticles to stabilize the lyophilized composition. These techniques may be used to prevent the need for cold chain storage and may also simplify the procedure at the clinic for reconstituting the vaccine to prepare an injectable composition.

NANOPARTICLE SURFACE TOPOGRAPHY MODIFIED WITH BOTTLEBRUSH BLOCK COPOLYMERS

Resumen de: US2025134822A1

A method to precisely tailor the surface topography of polymeric nanoparticles having bound thereto polyalkylene oxide, based on tuning the architecture of shape-persistent amphiphilic bottlebrush block copolymer (BBCP) building blocks, has been developed. It was demonstrated that nanoparticle formation and surface topography can be controlled by systematically changing structural parameters of BBCP architecture. The surface topography of PEGylated nanoparticles (nanoparticles having PEO or PEG covalently bound thereto) significantly affects their biological performance.

COMPOSITIONS COMPRISING A BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR

Resumen de: US2025135072A1

Disclosed herein are compositions comprising a polymer and a metabolic inhibitor, as well as a method of using the composition to modulate an immune response. The composition may be produced in the form of a synthetic tissue for provision in a subject. The composition or synthetic tissue may further comprise additional therapeutic agents.

PLANT TISSUE-DERIVED NANOFIBRES

Resumen de: US2025137169A1

Provided herein are nanofibres including self-assembled cellular components derived from a homogenized plant tissue. Methods for preparing such nanofibres, as well as uses thereof in the treatment or prevention of diseases or disorders in a subject and/or as delivery vehicles are also described.

Composition

Resumen de: AU2025202623A1

The present invention provides a pharmaceutical composition comprising a peroxisome proliferator activated receptor (PPAR) modulator and an polymeric nanocarrier component, wherein the polymeric nanocarrier component is capable of solubilising the PPAR modulator in an aqueous medium and, wherein in the polymeric nanocarrier component is a micelle forming non-ionic surfactant. Uses of the same in therapy are also provided.

LIPID COMPOSITION AND METHOD OF DELIVERING THERAPEUTIC AGENT

Resumen de: AU2023365462A1

It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.

NOVEL IONIZABLE LIPIDS

Resumen de: AU2023361218A1

The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.

MODIFIED OLIGONUCLEOTIDES

Resumen de: AU2023360051A1

The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.

NOVEL SECRETORY SIGNAL PEPTIDES

Resumen de: AU2023347284A1

Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.

COMPOSITIONS COMPRISING STEROL-AMINO-PHOSPHATE COMPOUNDS AND METHODS OF MAKING AND USE THEREOF

Resumen de: US2025135007A1

Disclosed herein are compositions comprising sterol-amino-phosphate compounds and methods of making and use thereof. Also disclosed herein are methods of making and methods of use of the compounds, compositions, and/or lipid particles disclosed herein. For example, the compounds and compositions are useful for treating a disease or disorder in humans and in animals. In some examples, the subject is a human male and the disease or disorder comprises male infertility.

Bioactive mitochondria encapsulated in a metal organic framework

Resumen de: US2025134925A1

According to an example aspect of the present invention, there is provided isolated bioactive mitochondria coated with a layer of Metal Organic Framework (MOF) and a method for intracellular delivery and release of said coated bioactive mitochondria in cells. The invention also provides a method for maintaining bioactivity and for increasing storage time of bioactive mitochondria by using MOF encapsulation.

miR-141-3p MODULATORS AND USES THEREOF

Resumen de: US2025136985A1

Disclosed herein is a pharmaceutically effective composition comprising at least one of a phosphorothioate (PS)-based anti-miR-141-3p oligonucleotide; a peptide nucleic acid (PNA)-based anti-miR-141-3p oligonucleotide; and/or a gamma-peptide nucleic acid (γ-PNA)-based anti-miR-141-3p oligonucleotide; where at least one of the foregoing oligonucleotides is encapsulated in a biocompatible nanoparticle.

IODIDE NANOPARTICLES AND COMPOSITIONS OF METHODS OF USE THEREOF

Resumen de: US2025135050A1

Iodide nanoparticles are provided. The nanoparticles can be potassium iodide (KI) nanoparticles, and can be formed of, a radioisotope, preferably 131I or 125I. The nanoparticles can include a coating that can increase the half-life of the particles, serve as a platform for attachment or entrapment of targeting moieties and/or additional active agents, or a combination thereof. Methods of use are also provided. For example, a method of treating a subject for cancer can including sensitizing the subject to radiation therapy by administrating the iodide nanoparticles to the subject in combination with one or more doses of radiation therapy. Methods of treating or imaging a subject can also include administering the subject an effective amount iodide nanoparticles, without the nanoparticles serving as radiosensitizer. In such methods, the nanoparticles typically include a radioisotope or an anticancer active agent, for example 131I, 125I, 124I, or 123I, or a chemotherapeutic agent.

USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

Resumen de: US2025134989A1

The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.

STABILIZED LIPID NANOPARTICLE MRNA COMPOSITIONS AND USES THEREOF

Resumen de: US2025134986A1

Provided herein are, inter alia, compositions or formulations comprising a nucleic acid (e.g. a RNA molecule) encapsulated in a lipid nanoparticle (LNP) and their uses.

IMMUNOGENIC MRNA DELIVERY VEHICLES

Resumen de: US2025134994A1

The present disclosure relates to lipid-based delivery vehicles for mRNA vaccines, which include a lysophosphatidylcholine (LPC) compound for enhancing vaccine immunogenicity. The present disclosure also relates to methods for use of the mRNA vaccines.

BIOSYNTHETIC HEMOSTAT AND USES THEREOF

Resumen de: US2025134969A1

A biosynthetic hemostat includes a plurality of biocompatible flexible nanoparticles wherein each nanoparticle includes a shell that defines an outer surface of the nanoparticle and a core, which is loaded with thrombin, and a plurality of von Willebrand factor-binding peptides (VBPs) and collagen-binding peptides (CBPs) that are linked to the shell and extend from the outer surface.

TUNABLE POLYMERIC NANOPARTICLES FOR TARGETED AND SUSTAINED DELIVERY OF GLYCOPEPTIDE ANTIBIOTICS

Resumen de: US2025135028A1

The present disclosure provides copolymers and glycopeptide antibiotic-loaded polymeric nanoparticles (PNPs) comprising the copolymers as well as charge neutral polymers for targeted and sustained delivery of glycopeptide antibiotics to treat bacterial infections, including but not limited to biofilm bacterial infections. The copolymers are block, alternate, or random copolymers comprising x units of the formulaand y units of the formulawherein Z is an organic moiety, R and R′ are each independently selected from the group consisting of hydrogen and C1-C18 alkyl, each of x and y is an integer of 1 or greater, the sum of x and y is an integer from about 40 to about 714, and y is from about 10% to about 90% of the sum of x and y.

SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Resumen de: US2025135017A1

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.

BEADS FOR TARGETED SIGNAL DELIVERY

Resumen de: US2025135027A1

Disclosed herein are cell-targeting complexes that are coated on the surface with target specific antibodies for induction of biological stimulus in target cells/tissue/organs. In some embodiments, the cell-targeting complex involves nonnucleated (e.g. platelets, red blood cells (RBC)) or enucleated cells that have been thiolated, streptavidinylated, and then coated with biotinylated antibodies. In some embodiments, the cell-targeting complex involves multilayer alginate hydrogel beads that have been coated with polyanionic proteins using a polycation, which is then thiolated, streptavidinylated, and then coated with biotinylated antibodies.

BEADED NONWOVEN MEMBRANE AS A DRUG DELIVERY SYSTEM

Resumen de: US2025134827A1

It relates to a beaded nonwoven membrane comprising polymeric nanofibers and at least one active agent, wherein the active agent has a water solubility equal to or lower than 33 mg/mL. It also relates to a process for the preparation of the beaded nonwoven membrane, and to its use in medical, and veterinary applications.

METHOD FOR PRODUCING MEDICATIONS AND VACCINES

Resumen de: US2025134825A1

The present invention relates to a method for producing a preferably lipid-based carrier system as well as to a corresponding carrier system, in addition to a composition or corresponding medicament based thereon, as well as to corresponding uses of the composition or medicant.

ANTI-COAGULATING HYDROGEL NANOFILM FOR CELL ENCAPSULATION

Resumen de: US2025134823A1

The present invention relates to a method for modifying and cross-linking an anticoagulating hydrogel nanofilm for cell encapsulation. According to the present invention, the protection from the external environment and the control of material transfer can be improved due to the anticoagulant functionalization of the material surface. In addition, when applied into the body, it can prevent fibrosis, blood coagulation, protein adsorption, and platelet adhesion caused by immune responses, thereby preventing a decrease in cell viability caused by immune responses and improving cell survival rate.

IONIZABLE LIPIDS AND IONIZABLE LIPID NANOPARTICLES

Resumen de: WO2025088570A1

A compound having the following structure of Formula (I) or a stereoisomer of the compound, tautomer of the compound, pharmaceutically acceptable salt thereof, wherein A1, A2, A3, R1a, R1b, R2a, R2b, m1, m2, m3, and X are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

LIPID NANOPARTICLES

Resumen de: WO2025088346A1

Provided is lipid nanoparticle functionalised with a glycopolymer. The glycopolymer comprises at least four carbohydrate units, wherein each carbohydrate unit is independently selected from a monosaccharide, a disaccharide and an oligosaccharide. The lipid nanoparticle can be used for inducing an immune response in a subject.

METHODS FOR THE COUPLING OF DI(ALKYL)AMINES TO POLYPEPTIDES

Resumen de: WO2025088192A1

The present invention provides for inventive means and methods for the coupling of di(alkyl)amines to polypeptides or peptides capable of forming a random coil conformation. The present invention further provides inventive compounds produced by the herein detailed methods, wherein said compounds are characterized by formula (I): A-B-bC-D. Said compounds comprise a polypeptide/peptide capable of forming a random coil conformation, an N-terminal protecting group, a di(alkyl)amino group, and optionally a linker. Furthermore, the present invention provides lipid nanoparticles comprising said compounds characterized by formula (I) as well as means and methods for the production of said lipid nanoparticles. Formulations comprising the inventive compounds and/or the lipid nanoparticles of the present invention are also provided. Further, the present invention also relates to uses of the inventive compounds, the lipid nanoparticles, and/or the formulations disclosed herein.

SUGAR-CONJUGATED LIPID NANOPARTICLES AND METHODS OF USE THEREFOR

Resumen de: WO2025091046A1

Provided are compositions that include compositions of galactosyl -conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl- conjugated LNPs have a lipid component having D-Lin~MC3-DMA, ALC-0315 and. SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc -conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated, with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited, to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.

A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND, AND RELATED METHODS THEREOF

Resumen de: WO2025090023A1

There is provided a compound comprising a structure represented by general formula (1) or an ionized form thereof for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein R5 and each R6 are independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; R3, and each R7 are independently optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene; n is from 0 to 100; l and m are each independently 0 or 1; each A is independently selected from H, aliphatic alcohol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an epoxy ring- opening product and/or derivatives thereof; and B is R1R2N- or R23O- where R1 and R2 are each independently H, or a hydrophobic tail with the proviso that both of R1 and R2 are not H at the same 116 time; and where R23 is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

HYDROGEL CELL MIMICS WITH SUBCELLULAR FEATURES

Resumen de: WO2025090968A1

Bead-in-particles formats and their use in cytometric applications are described. In one aspect, the disclosure provides a bead-in-particle comprising an outer hydrogel body and an inner hydrogel bead. As described herein, the bead-in-particle is selectively tuned to have at least one morphological property substantially similar to subcellular macrostructures of interest present in a target cell. In one aspect of the disclosure, the bead-in-particle are used as a calibration reagent for the detection of a target cell in a sample, such as by image-based flow cytometry.

BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090417A1

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME

Resumen de: WO2025090663A1

The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.

球状ナノ構造体

Resumen de: CN118843482A

The present disclosure relates to a plurality of nanostructures having an average hydrodynamic diameter between 20 nm and 50 nm, wherein each nanostructure is a polymeric nanostructure comprising a central portion, an anchor layer surrounding the central portion, and a coating surrounding the anchor layer. The disclosure also relates to the use of such a plurality of nanostructures as a medicament, in particular for cancer treatment and/or imaging, as well as the use of such nanostructures as carriers for radionuclides. The present disclosure also relates to methods and kits for radiolabeling such nanostructures with multivalent cationic radionuclides.

アンカー層を有する球状ナノ構造体

Resumen de: CN118843456A

The present disclosure relates to a plurality of spherical nanostructures. Each nanostructure comprises a central portion comprising a polymer backbone according to monomer residues of {(OR1) (OR2) PO} 2-(C) {(CH2) mSi (OR3) 3} {(CH2) mSi (OR3) 3} wherein each R1 and R2 are independently selected from the group consisting of a negative charge and H; each R3 is independently selected from the group consisting of a negative charge, H, and a covalent bond bound to a polymer backbone; wherein at least 3 R3 are bonds bound to the polymer backbone; and m is an integer between 1 and 5; and wherein the central portion of the nanostructure has a volume average hydrodynamic diameter of 10 nm to 90 nm; and an anchor layer surrounding the central portion, where the anchor layer includes a polymer according to monomer residues of (RO) 3Si-(CH2) n-Si (OR) 3, where each R is independently selected from the group consisting of negative charges, H, and covalent bonds, wherein at least two R are independently selected from the group consisting of a covalent bond bonded to a monomer residue of the central portion and a covalent bond bonded to a monomer residue of the anchor layer; wherein-represents a covalent bond; n is 1 or 2; and wherein the anchoring layer has a thickness of from 1 nm to 5 nm. The present disclosure also relates to methods of making such nanostructures as well as uses of the nanostructures, and to pharmaceutical compositions comprising such nanostructures.

COMBINATION THERAPIES

Resumen de: AU2022463987A1

The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.

CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA

Resumen de: AU2023288520A1

Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

LIPID STRUCTURES AND COMPOSITIONS COMPRISING SAME

Resumen de: AU2023288487A1

The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, stabilization lipids and structural lipids, and a therapeutic agent, such as a nucleic acid, for delivery to mammalian cells or organs are described.

遺伝子治療のためのＩＲＡＫ４モジュレーターの使用

Resumen de: MX2024012616A

Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK modulator (e.g., an IRAK-4 degrader) with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno- associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK modulator in combination with a gene therapy agent.

NANOBODY AND NANOBODY-DRUG CONJUGATE TARGETING CD73, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: EP4545561A1

The present invention relates to a novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated CD73, various tumor cells and CD73 on the surface of an immune cell with high specificity and block the catalytic activity of CD73 enzymes, exhibiting high affinity, low immunogenicity, and a significant anti-tumor effect.

遺伝子治療のためのＩＲＡＫ４モジュレーターの使用

Resumen de: MX2024012617A

Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK degrader with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK degrader in combination with a gene therapy agent.

PREVENTION AND/OR TREATMENT OF CARDIAC DAMAGE

Resumen de: WO2023247047A1

The present invention refers to a peptide, comprising or consisting of SEQ ID NO: 1 (CAYMTMKIRN), for use as a medicament, preferably in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion, or in the prevention and/or treatment of the inflammatory response following acute myocardial infarction. In a preferred embodiment, the peptide is conjugated with a nanoparticle.

狂犬病ウイルス感染症の予防及び治療のための組成物及び方法

Resumen de: MX2024012693A

The present disclosure relates generally to the field of molecular virology, and in particular relates to nucleic acid molecules encoding a modified alphavirus viral genome or self-replicating RNA construct (srRNA), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for the production of desired products in cell cultures or in a living body. Also provided are methods of eliciting an immune response in a subject in need thereof, as well as methods of preventing and/or treating rabies virus infection.

RAPIDLY DISSOLVING AND ORODISPERSIBLE NANOFIBERS LOADED WITH RISPERIDONE PRODUCED BY ELECTROSPINNING METHOD

用于光热疗法的自组装纳米粒子

Resumen de: CN119899218A

本文描述了作为光热转导剂的环金属化铁(II)络合物。所公开的络合物表现出高结构稳健性和在近红外(NIR)和可见光区域的显著吸收。所描述的络合物可以自组装以形成金属超分子粒子，其具有优异的光热性能并可以通过EPR效应靶向肿瘤。例如，本文公开的Fe NP具有强的近红外(NIR)吸光度，在近红外(例如，808nm)激光照射下具有至少30％(例如约60％)的高光热转换效率和/或优异的光热稳定性。Fe NP可以用包衣剂(例如牛血清白蛋白)包衣以形成包衣的Fe NP，这可以进一步增强金属超分子粒子在体内的肿瘤积累和生物相容性。Fe NP的优异光热性能使其能够解决与大多数现有光热材料相关的光热转换效率低的问题。

一种高效表达GBA1的mRNA及其应用

Resumen de: CN119899835A

本申请公开了一种高效表达GBA1的mRNA及其应用。本申请高效表达GBA1的mRNA由5’端至3’端依序包括5’甲基化帽子、5’UTR、目的基因序列、3’UTR和polyA尾巴；其中，目的基因序列为编码GBA1蛋白或GBA1突变蛋白的序列。本申请高效表达GBA1的mRNA，通过修改mRNA不同元件来获得更稳定、表达效率更高的GBA1mRNA。

一种基于磷酸钙介导的外泌体药物递送系统及制备方法

Resumen de: CN119896651A

本发明属于生物技术技术领域，具体涉及一种基于磷酸钙介导的外泌体药物递送系统，并进一步公开其制备方法与应用。本发明所述基于磷酸钙介导的外泌体药物递送系统，通过Ca2+和磷酸盐构建形成磷酸钙介导的外泌体递送体系，通过氯化钙转染miRNA后可以将核酸药物载入到外泌体中，外泌体中miRNA的含量显著提高，进而借助于外泌体的递送性能将药物运输，有效提高了药物的载药效率和递送效率，具有装载效率高的优势。

一种基于脐带间充质干细胞囊泡负载I型光敏前药的纳米囊泡及其制备方法与应用

Resumen de: CN119899206A

本发明公开了一种基于脐带间充质干细胞囊泡负载I型光敏前药的纳米囊泡及其制备方法与应用，其包括来源于人脐间充质干细胞的囊泡及其负载的所述I型光敏前药。本发明的优点包括：纳米囊泡EVs@NBS‑PB的I型光敏前药可与糖尿病慢性伤口微环境中高水平的H2O2响应释放I型光敏剂，再通过激光激发后产生PDT效应释放活性氧达到抗菌的目的，实现对糖尿病慢性创面的靶向抗感染作用，结合来源于人脐间充质干细胞的囊泡调节伤口微环境来协同治疗慢性创面；干细胞囊泡不仅能够提高光敏前药的生物相容性，同时还具有促细胞增殖、迁移及血管生成的作用；用水凝胶微针贴片装载给药的方式不仅具有高药物递送效率和微创性，同时也能提高患者的依从性。

AGREGADO DE NANOPARTICULAS POLIMERICAS, SU PROCEDIMIENTO DE OBTENCION Y SU USO EN EL TRATAMIENTO DE TROMBOEMBOLISMO VENOSO

一种液态金属纳米颗粒光热材料的制备方法

Resumen de: CN119896731A

本发明属于光热材料制备技术领域，具体涉及一种液态金属纳米颗粒光热材料的制备方法，包括：步骤1、配制海藻酸钠水溶液；步骤2、在海藻酸钠水溶液中加入镓基液态金属，先通过搅拌混合，再通过超声处理充分混合；步骤3、干燥后得到生成物。本发明的制备过程是在常规环境下制备，对环境的要求低。另外，本发明制备的纳米颗粒具有稳定性好、光热性能佳、制备方法简单、形成速率快、易控制的特点，可制备具有高效光热能力的材料。综合以上有益效果，本发明在光热材料制备技术领域具有良好的应用前景。

用于递送的脂质化合物和脂质纳米颗粒

Resumen de: CN119874554A

本申请公开了一种化合物，结构式如式(I)所示，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其药学上可接受的盐或其立体异构体的纳米颗粒组合物，本申请的纳米颗粒可以高效递送药物、疫苗至细胞内，发挥药物、疫苗的治疗或预防目的。#imgabs0#

一种含有抗氧化剂和siRNA的纳米复合物及其制备方法和应用

Resumen de: CN119868302A

本发明涉及生物医用材料领域，公开了一种含有抗氧化剂和siRNA的纳米复合物及其制备方法和应用。其制备方法包括：以含有氨基的抗氧化剂和含有苯硼酸结构的化合物为原料，在鎓盐类酰胺化偶联剂催化下得到苯硼酸键修饰的抗氧化剂；将苯硼酸键修饰的抗氧化剂和含有邻二酚结构的脂质在有机溶剂中反应，得到抗氧化剂偶联的脂质；将该脂质和阳离子脂质混合，溶于低沸点有机溶剂，再加入含有siRNA MMP9的DEPC水溶液，超声、减压浓缩，得到含有抗氧化剂和siRNA的纳米复合物。本发明所制备的纳米复合物仅使用两种不同功能的脂质通过静电作用，即可实现对siRNA的有效负载，具有制备方法简单、有效成分明确、生物相容性良好等优点等。

一种基于幽门螺杆菌外膜囊泡的纳米疫苗及其制备方法与应用

Resumen de: CN119868526A

本发明属于疫苗制备领域，具体涉及一种基于幽门螺杆菌外膜囊泡的纳米疫苗及其制备方法与应用。本发明以幽门螺杆菌的OMV和LPS为抗原和佐剂，以DMON为载体，然后利用静电相互作用使DMON吸附LPS小分子，再利用脂质体挤出器将幽门螺杆菌OMV均匀包裹在DMON纳米材料表面，得到基于幽门螺杆菌外膜囊泡的纳米疫苗。本发明通过体内外试验证明该纳米疫苗能够被巨噬细胞摄取，促进巨噬细胞的吞噬能力，显著提高巨噬细胞分泌各种免疫细胞因子的水平，能在小鼠体内诱导高水平的抗原特异性体液免疫、黏膜免疫以及Th1/Th2/Th17型细胞免疫应答。

用于递送的脂质化合物和脂质纳米颗粒

Resumen de: CN119874553A

本申请公开了一种化合物，结构式如式(I)所示，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其药学上可接受的盐或其立体异构体的纳米颗粒组合物，本申请的纳米颗粒可以高效递送药物、疫苗至细胞内，发挥药物、疫苗的治疗或预防目的。#imgabs0#

一种脂质纳米颗粒及其应用

Resumen de: CN119876277A

本发明提供了一种脂质纳米颗粒及其应用。本申请对脂质材料配方的比例、最优细胞培养及编辑体系、编辑系统Cas9mRNA：sgRNA比例、Cas9mRNA设计优化进行一系列探索，摸索出适合于针对人造血干细胞转染及编辑的系统，本申请在节约成本的同时，可完全替代目前已有的市面转染试剂不能有效转染原代细胞的问题，实现原代细胞内编辑效率的显著提高，进而能在体内得到很好的治疗效果。

一种噻吩取代的氮杂氟硼二吡咯化合物、化合物的纳米颗粒及它们的制备方法和应用

Resumen de: CN119874742A

本发明公开了一种噻吩取代的氮杂氟硼二吡咯化合物、化合物的纳米颗粒及它们的制备方法和应用。本发明设计并合成的噻吩取代的氮杂氟硼二吡咯化合物，噻吩基团的引入可以使氮杂氟硼二吡咯的吸收光谱显著红移，成功红移至810nm近红外区域，更有利于其在生物体内以及光热治疗方面的应用。以该化合物为内核制备的纳米颗粒在局部腹腔给药后可以有效地分布到内脏脂肪组织，选择性地靶向内脏脂肪组织，具有良好的生物相容性和较高的光热转换效率，可以通过调节其浓度和808nm激光功率实现对温度的调控，可用于光热治疗肥胖。

一种用于抑制新生血管生成的自组装多肽及其制备方法和应用

Resumen de: CN119874811A

本发明涉及一种用于抑制新生血管生成的自组装多肽及其制备方法和应用，所述自组装多肽包括疏水单元、组装单元、特异性靶向Tie2受体的多肽和特异性靶向VEGFR2受体的多肽。本发明提供的自组装多肽同时靶向Tie2受体和VEGFR2受体，特异性靶向血管内皮细胞，在亲疏水作用下自组装形成纳米颗粒，经过配受体相互作用后，由纳米颗粒转变为纳米纤维，阻碍VEGF结合VEGFR2和Ang2结合Tie2，实现在新生血管病灶区域的快速富集，抑制内皮细胞迁移，进而抑制血管的生成。

一种雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料及其应用

Resumen de: CN119868303A

本申请公开了一种雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料及其应用，属于纳米材料合成领域。该雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料为纳米级颗粒，呈方块状结构，包括方块状普鲁士蓝纳米颗粒和包覆在普鲁士蓝纳米颗粒外的雷公藤外泌体样纳米囊泡。通过将雷公藤外泌体纳米囊泡PELNVs加入到普鲁士蓝纳米颗粒溶液中混合，将混合后的体系采用物理挤压使其反复通过聚碳酸酯膜制备得到。所得雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料具备优异的光热转换性能和抗氧化性能，且溶血率保持极低水平，细胞毒性低，用于类风湿关节炎光热治疗，具有优异的光热治疗能力，生物安全性好，应用前景广泛。

一种白蛋白维替泊芬纳米粒的制备方法及其应用

Resumen de: CN119868544A

本发明涉及生物医药技术领域，尤其涉及一种白蛋白维替泊芬纳米粒的制备方法及其应用。白蛋白维替泊芬纳米粒在治疗肿瘤中的应用；白蛋白维替泊芬纳米粒的制备方法，步骤如下：将白蛋白聚合物水溶液与维替泊芬高速搅拌反应，并通过100kDa超滤管纯化。本发明提供的一种白蛋白维替泊芬纳米粒的制备方法及其应用，制得的白蛋白维替泊芬纳米粒，其仅能明显增加穿过细胞的药物量，进入细胞后维替泊芬的光动力效应还具有抗肿瘤效果。

T细胞的活化/增殖方法

Resumen de: MX2021004357A

The present invention provides: a method which is for the activation and/or proliferation of T cells and includes a step for bringing a T cell-containing cell population into contact with a nucleic acid delivery carrier having a surface to which at least one T cell-activating ligand is added; a method which is for delivering a nucleic acid into a T cell and includes a step for bringing a T cell-containing cell population into contact with (a) a nucleic acid delivery carrier that has a surface to which at least one T cell-activating ligand is added and that contains a nucleic acid therein, or (b) both of at least one T cell-activating ligand and a nucleic acid delivery carrier that has a surface to which a T cell-activating ligand is not added and that contains a nucleic acid therein; and a method for producing a medicament that contains T cells.

一种兽用复方黄芪多糖注射液及其生产工艺

Resumen de: CN119868272A

本发明公开了一种兽用复方黄芪多糖注射液及其生产工艺，属于兽用医药配制品技术领域，包括如下步骤：将黄芪多糖溶解后与复合纳米颗粒复合得到黄芪多糖负载粉末；将表面活性剂和无水乙醇加入液体石蜡中，将分散液边搅拌边加入反应釜中，然后搅拌得到复方黄芪多糖注射液；本发明的生产工艺通过将环糊精制备成载体吸附和封装黄芪多糖，并利用环糊精载体的吸附能力与聚乳酸形成核壳结构，将包覆有纳米硒的聚乳酸负载在环糊精载体内，既阻止了纳米硒在注射液中的团聚，也使黄芪多糖分散性提高，通过将复合纳米颗粒制备成乳液，提高复合纳米颗粒的分散性，乳液形态的注射液更容易被动物吸收，使纳米硒与黄芪多糖产生协同作用，提高动物的抵抗力。

PEDV与TGEV环状RNA二联苗的创制与应用

Resumen de: CN119876208A

本发明公开了PEDV与TGEV环状RNA二联苗的创制与应用。本发明提供的疫苗组合物由PEDV环状RNA疫苗和TGEV环状RNA疫苗组成，其可以同时防治猪流行性腹泻病毒、猪传染性胃肠炎病毒两种传染病，与单苗相比，二联疫苗组合物没有产生免疫干扰现象，疫苗免疫效果没有下降，可以避免多次接种免疫出现的不良反应，具有广泛的应用价值。

一种调控缺血微环境的工程化血小板膜纳米载体及其制备方法

Resumen de: CN119868305A

本发明提供一种调控缺血微环境的工程化血小板膜纳米载体及其制备方法。所述工程化血小板膜纳米载体由纳米颗粒(DY)和形成于所述纳米颗粒(DY)表面的血小板膜组成，其中，所述纳米颗粒(DY)通过长链分子DSPE‑PEG2000‑Arg‑TK‑CY‑09自组装形成，TK表示ROS响应材料硫缩酮键，CY‑09表示抑制NLRP3炎症小体活化及组装的抗炎药物CY‑09，Arg表示产生NO的L‑Arg，DSPE‑PEG2000表示两亲性聚合物。本发明所提供的工程化血小板膜纳米载体(DY@PM)具有较高的稳定性和生物安全性，可靶向病灶部位，多靶点协同调控缺血微环境，在生物医学领域具有广阔的应用前景。

具有抗菌功能的含铁脂质纳米粒IO-LNPs的制备方法和应用

Resumen de: CN119868304A

本发明属于纳米技术领域，具体公开了一种具有抗菌功能的含铁脂质纳米粒IO‑LNPs的制备方法和应用。以油酸铁、大豆卵磷脂和DSPE‑MPEG2000为原料，通过梯度溶剂扩散法合成了具有抗菌功能的含铁脂质纳米粒(IO‑LNPs)，其能诱导细菌铁死亡效应，具有良好的抗菌活性，能够有效杀灭革兰氏阳性(S.aureus，)和阴性(E.coli)菌株，而且对S.aureus和E.coli具有良好的生物膜预防和破坏能力。本发明制备的具有抗菌功能的含铁脂质纳米粒IO‑LNPs在生理条件下表现出较高的稳定性和生物相容性，在抗菌性能上具有优异的效果，是对抗细菌感染和促进伤口愈合的安全高效的药剂。

一种包埋γ-氨基丁酸的木薯淀粉-β-环糊精纳米微粒的制备方法和应用

Resumen de: CN119868310A

本发明公开了一种包埋γ‑氨基丁酸的木薯淀粉‑β‑环糊精纳米微粒的制备方法和应用，所述的制备方法包括如下步骤：步骤一）、用木薯淀粉悬浮液和β‑环糊精制备纳米微粒，再制成溶液；步骤二）、制备γ‑氨基丁酸溶液，制备得到的γ‑氨基丁酸溶液与步骤一）的纳米微粒溶液混合。本发明的γ‑氨基丁酸的木薯淀粉‑β‑环糊精纳米微粒可以提高γ‑氨基丁酸的稳定性，进一步改善γ‑氨基丁酸提高睡眠质量的效果，在医药生产中具有实际应用价值。

适用于三组分脂质纳米颗粒的脂质化合物及其应用

Resumen de: CN119874800A

本发明涉及药物输送领域，具体涉及一种脂质化合物、包含该脂质化合物的药物组合物及其制剂和应用。将本发明提供的脂质化合物应用于脂质纳米颗粒系统中，可以将传统的四组分脂质纳米颗粒变为三组分脂质纳米颗粒，提高脂质纳米颗粒药物递送系统的制备效率，并同时具有较好的安全性。

杂化纳米颗粒及其制备方法、用途

Resumen de: CN119868307A

本发明涉及生物医用领域，具体提供一种杂化纳米颗粒及其制备方法、用途，旨在解决循环血液中的乳酸过多对败血症治疗过程的不良影响。为此目的，本发明的杂化纳米颗粒的制备方法包括：制备聚丙烯胺盐酸盐改性的中空介孔二氧化锰；合成柱5芳烃功能化透明质酸；在所述聚丙烯胺盐酸盐改性的中空介孔二氧化锰上负载乳酸氧化酶，得到中间体；在所述中间体的表面通过静电相互作用包被所述柱5芳烃功能化透明质酸，得到杂化纳米颗粒。本发明提供的杂化纳米颗粒制备简便、成本低廉，可广泛应用于材料学、生物学、医学等领域，具有良好的生物相容性；能够以双管齐下的乳酸清除方式有效下调循环血液乳酸浓度，有望在体内实验中有效控制LPS诱导的败血症进程。

用于核酸递送的2-氨基丙烷-1,3-二醇封端的阳离子类肽

Resumen de: AU2023337954A1

The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.

用于核酸治疗的脂质纳米颗粒(LNP)组合物或制剂

Resumen de: WO2024044178A1

The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.

脂质化合物和脂质纳米颗粒组合物

Resumen de: TW202434543A

The present application discloses a compound with a structural formula as shown in formula (I), and a salt or an isomer thereof. The present application also discloses a nanoparticle composition containing the compound and a salt or an isomer thereof. The nanoparticle composition of the present application can efficiently deliver drugs into cells and exert therapeutic or prophylactic effects of drugs.

一种同时递送光敏剂和靶向抗体的纳米颗粒及其制备方法和应用

Resumen de: CN119868309A

一种同时递送光敏剂和靶向抗体的纳米颗粒及其制备方法和应用。本发明提供的纳米颗粒，含有光敏剂、一氧化氮前体、siRNA、和巨噬细胞膜，所述光敏剂为焦脱美叶绿素a分子，所述siRNA为siPD‑L1，所述一氧化氮前体为九聚精氨酸。本发明提供的靶向纳米颗粒可实现光敏剂和siRNA的高效递送。本发明将精氨酸与焦脱镁叶绿酸a按1:1共价连接，制备纳米粒后，通过静电吸附原理负载带负电的siPD‑L1，通过包裹M1巨噬细胞膜囊泡，降低纳米颗粒表面电荷同时提高纳米颗粒的肿瘤靶向能力。在650nm激光照射下可实现光动力和抗PD‑L1免疫联合治疗恶性肿瘤。

脂质化合物和脂质纳米颗粒组合物

Resumen de: TW202440536A

The present application discloses compounds of formula (I), as well as salts and stereoisomers thereof, wherein the variables are as defined in the specification. The present application also discloses nanoparticle compositions comprising the compounds or salts or stereoisomers thereof, and the use of the nanoparticle compositions for delivering active agents.

一种负载过氧化铜的自佐剂化纳米药物及制备方法与应用

Resumen de: CN119868306A

本发明公开了一种负载过氧化铜的自佐剂化纳米药物及制备方法与应用，制备方法包括：制备酰肼化透明质酸；将酰肼化透明质酸经配位和静电吸附作用修饰于纳米氮化铝表面，得到透明质酸化纳米氮化铝；将透明质酸化纳米氮化铝通过铜‑酰肼配位/矿化反应原位制备负载过氧化铜的自佐剂化纳米药物。该纳米药物能响应肿瘤微环境发生分解，进而消耗谷胱甘肽、自供过氧化氢、自生成纳米佐剂、中和肿瘤酸性，可经氨毒性和类芬顿催化活性实现抗肿瘤治疗应用。

一种近红外二区AIE探针与光激活治疗膀胱癌的纳米材料

Resumen de: CN119874723A

本发明提出了一种近红外二区AIE探针与光激活治疗膀胱癌的纳米材料，属于材料化学技术领域，针对光热疗法对膀胱癌治疗效果不佳的问题，本发明设计了一种能够在近红外二区进行高效光热转化的AIE探针，并在其基础上将AIE探针与热敏NO供体共混，将近红外光诱导光热转换释放NO；用两亲性聚合物封装后再修饰细胞膜表面PMCA钙离子通道阻断肽和肿瘤表面FGFR1受体靶向肽，细胞膜表面PMCA钙离子通道阻断肽与热敏NO供体释放的NO共同作用，通过内源性与外源性联合调节钙离子通路，造成肿瘤钙超载，诱导肿瘤细胞凋亡；表面修饰的肿瘤表面FGFR1受体靶向肽可实现该纳米材料在肿瘤部位高效富集，提高治疗效果。本发明所提供的材料为膀胱癌治疗提供了新的思路。

一种两亲性氮杂氟硼荧类荧光染料及其制备方法和应用

Resumen de: CN119874737A

本发明公开了一种两亲性氮杂氟硼荧类荧光染料及其制备方法和应用；通过在氮杂氟硼荧类荧光结构中引入两个四甘醇作为亲水结构，引入四个C8或者C18的烷基链作为疏水基元，通过慢加水或者闪沉方式可以组装得到纳米粒子，纳米片以及支化纳米棒结构，并且这些纳米结构在808nm处有非常强的吸收，具有优异的光热转换效果，可以用于肿瘤的光热治疗。

一种重组脂质纳米粒及其制备方法和应用

Resumen de: CN119868308A

本发明属于生物医药技术领域，公开了一种治疗缺血性脑卒中的重组脂质纳米粒及其制备方法和应用。本发明以芹菜籽(Celery seeds，CS)为原材料采用有机溶剂提取法提取脂质，再通过乙醇注入法成功制备芹菜籽重组脂质纳米粒(CS‑rLNPs)。本发明公开的提取工艺简单，原料易得，制备的纳米药物CS‑rLNPs具有生物安全性、稳定性好等优点；经体内外实验表明，CS‑rLNPs能有效穿透血脑屏障和优先分布到缺血半暗区，并能够与脑缺血区域的神经元结合，表现出独特的神经元靶向性；除此之外，该纳米粒对缺血性脑卒中的治疗具有实用价值。因此，本发明的重组脂质纳米粒具有良好的临床应用价值和前景。

用于持续释放抗体的单体式可植入器件

Resumen de: WO2023244526A1

A monolithic implantable device for delivery of an antibody is provided. The implantable device comprises a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents and optionally, one or more excipients. The therapeutic agents contain an antibody and the polymer matrix contains a hydrophobic polymer. Within a time period of 35 days, the device exhibits a cumulative weight-based release ratio of the antibody of from about 20% to about 60%.

POLYNUCLEOTIDE MOLECULE FOR PREVENTING OR TREATING HPV INFECTION-RELATED DISEASES

Resumen de: TW202432572A

The present application relates to the field of biotechnology, specifically to an mRNA vaccine for treating HPV infection related diseases by inducing HPV antigen-specific immune responses.

NANOPARTICLES CAPABLE OF REALIZING CONTROLLED RELEASE OF CARBON MONOXIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2025081381A1

Nanoparticles capable of realizing controlled release of carbon monoxide, and a preparation method therefor and the use thereof. The nanoparticles capable of realizing controlled release of carbon monoxide comprise triiron dodecarbonyl and Croc-PEG that coats triiron dodecarbonyl, wherein Croc-PEG is a condensation product of Croc and MPEG-NH2. The nanoparticles capable of realizing controlled release of carbon monoxide can effectively improve the loading capacity of carbon monoxide, thereby achieving controlled release of carbon monoxide and high-efficiency low-toxicity CO gas therapy.

TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA

Resumen de: AU2025202461A1

Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAIl or DNAH5.

PSMA LIGAND TARGETED COMPOUNDS AND USES THEREOF

Resumen de: US2025127935A1

Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.

DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO

Resumen de: US2025127925A1

Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

Telmisartan Nanosuspension for Therapy of Respiratory Infections and Methods of Making and Using Same

Resumen de: US2025127761A1

A method of inhibiting viral replication of a virus in an individual comprising administering an effective amount of a drug nanosuspension combined with a surfactant, wherein the drug nanosuspension combined with the surfactant is delivered to the individual's lungs. Preferably, the drug is a nanosuspension delivered to the individual's lungs through inhalation.

Self-Assembling Nanoparticles Based On Amphiphilic Peptides

Resumen de: US2025127887A1

The present disclosure relates to a vaccine comprising an amphiphile having the formula S-B-U-H and at least one peptide antigen conjugate having the formula selected from S-E1-A-E2-U-H and H-U-E1-A-E2-S, wherein the amphiphile and/or the at least one peptide antigen conjugate comprises a dendron amplifier. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, an infectious disease, a cardiovascular disease, or a neurodegenerative disease.

PH-RESPONSIVE NANO PARTICLE FOR DELIVERY OF RIBONUCLEOPROTEINS

Resumen de: US2025127921A1

Provided herein are self-assembled nanoparticles (NPs), pharmaceutical compositions containing such NPs and methods of using such NPs. The NPs comprise an amphiphilic copolymer and a ribonucleoprotein (RNP), and optionally ssODN, wherein: the amphiphilic copolymer is a water-soluble block copolymer comprising a poly(C2-3 alkylene glycol) block and an acrylic block comprising a poly(acrylate), poly(methacrylate) or poly(acrylate/methacrylate) block; the acrylic block comprise ester side chains bearing substituted or unsubstituted alkylamine groups; and the RNP, ssODN, and the acrylic block of the amphiphilic copolymer form a core of the self-assembled nanoparticle, and the poly(ethylene glycol) block of the amphiphilic copolymer forms the exterior of the self-assembled nanoparticle.

NUCLEIC ACID-LIPID NANOPARTICLE AND METHOD USING THE SAME

Resumen de: US2025127882A1

A nucleic acid-lipid nanoparticle is provided, which comprises: a nucleic acid molecule and a lipid mixture. The lipid mixture comprises: an ionizable amino lipid present in an amount of 20 mol % to 60 mol %; a phospholipid present in an amount of 5 mol % to 20 mol %; cholesterol present in an amount of 25 mol % to 60 mol %; and a PEGylated lipid present in an amount of 0.2 mol % to 6 mol %. In addition, methods using the aforesaid nucleic acid-lipid nanoparticle are also provided.

METHODS OF LOADING EXTRACELLULAR VESICLES

Resumen de: US2025127919A1

The present disclosure relates to methods of loading an EV with a payload. In some aspects, the payload and the EV are mixed at a specific loading condition (e.g., at the disclosed salt concentrations, loading temperature, loading duration, payload feed concentration, and/or EV feed concentration), such that the amount of the payload that is associated with the exterior surface of the EV is increased. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

HYPERACTIVATING LIPID NANOPARTICLES

Resumen de: US2025127868A1

The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one further lipid, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising a LPC and at least on further lipid, in which the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.

NANOPARTICLE VECTOR FOR RNA SELF-DELIVERY, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: US2025129386A1

The present disclosure discloses a nanoparticle vector for RNA self-delivery and a preparation method therefor and use thereof. The nanoparticle vector includes: a β-cyclodextrin-RNA conjugate, an adamantane-ligand conjugate, and a cationic polymer, wherein the adamantane-ligand conjugate is formed by conjugating adamantane with a ligand molecule through polyethylene glycol. Through a host-guest interaction between β-cyclodextrin and an adamantane molecule, the nanoparticle vector can realize the modular conjugation of a delivered RNA molecule and the ligand molecule, and realize the self-delivery of RNA. The polyethylene glycol molecule can avoid the recognition and phagocytosis of immune cells before the vector enters target cells, and β-cyclodextrin can realize the escape of intracellular nucleosome. The nanoparticle vector delivers RNA to cells in a targeted manner, and is degraded in vivo via endocytosis, releasing RNA molecules to inhibit expression of genes of interest, and play a role in repairing cartilage and bone tissue in situ.

Constrained Ionizable Cationic Lipids and Lipid Nanoparticles

Resumen de: US2025127728A1

Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is an LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.

IONIZABLE LIPIDS WITH BIOACTIVE MOTIFS

Resumen de: US2025127727A1

Provided are ionizable lipids containing a piperazine moiety, as well as lipid nanoparticles that can be formed using the ionizable lipids for use in delivering nucleic acids and other therapeutic agents to specific cell types.

ANISAMIDE-CONTAINING LIPIDS AND COMPOSITIONS AND METHODS OF USE THEREOF

Resumen de: US2025127719A1

The present disclosure relates to ionizable lipidoid compounds comprising an anisamide moiety, and lipid nanoparticles (LNPs) comprising the same. In certain embodiments, the LNP selectively binds to at least one sigma receptor. In certain embodiments, the LNP specifically targets a cell of interest (e.g., a cell expressing a sigma receptor, fibroblast, cancer cell, stromal cell, and epithelial cell, inter alia). In another aspect, the present disclosure provides methods for in vivo delivery of therapeutic agents to treat, prevent, and/or ameliorate diseases and/or disorders, including but not limited to fibrosis and cancer.

IONIZABLE LIPID NANOPARTICLES FOR IN UTERO mRNA DELIVERY

Resumen de: US2025127720A1

Disclosed herein is a method for the delivery of prenatal therapeutics, enzyme replacement therapy, or gene therapy to a fetus in need thereof. The method comprises introducing ionizable lipid nanoparticles (LNPs) nanoparticles comprising a therapeutic mRNA composition into the circulation of the fetus in need of treatment such that the ionizable LNPs deliver the therapeutic mRNA composition.

5T4 NANOBODY AND USE THEREOF

Resumen de: WO2025082447A1

Provided are a nanobody targeting 5T4 and a use thereof. Specifically, provided are an anti-5T4 nanobody, and a long-acting anti-5T4 nanobody formed by linking the anti-5T4 nanobody with an anti-serum-albumin nanobody in tandem. Furthermore, the antibody can be used for preparing an antibody-drug conjugate and constructing a chimeric antigen receptor and an engineered immune cell expressing the chimeric antigen receptor. The antibody, the antibody-drug conjugate, and the engineered immune cell can be used for preparing a drug for treating and/or preventing diseases or disorders associated with 5T4, such as solid tumors and malignant hemopathies.

LIPID COMPOUND AND LIPID NANOPARTICLE FOR DELIVERY

Resumen de: WO2025082397A1

The present application discloses a compound having a structural formula as shown in formula (I), and a salt and isomer thereof. The present application also discloses a nanoparticle composition comprising the compound or the salt or isomer thereof. The nanoparticle of the present application can efficiently deliver an active ingredient into a cell to achieve the purpose of treatment or prevention.

LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE

Resumen de: WO2025083657A1

The present invention relates to a novel lipid compound for tissue-specific delivery and a lipid nanoparticle (LNP) including same. The lipid nanoparticle includes, as a component, a lipid compound modified such that an active substance therein is selectively delivered into cells of a specific tissue such as lymph nodes, the spleen, the retina, cancer, the brain, the liver, and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effects. These tissue-specific, non-viral LNP carriers can be effectively utilized for the prevention of infectious diseases and the treatment of rare and intractable (hereditary) diseases (macular degeneration, diabetic retinopathy, hereditary retinal degeneration, cancer, brain diseases, liver diseases, and etc.), where targeted and selective delivery within the body is crucial.

BIO-PARTICLE ENCAPSULATED HYDROGEL USING AQUEOUS-TWO PHASE SYSTEM AND METHOD FOR PRODUCING SAME

Resumen de: WO2025084854A1

When a biological material sensitive to an external reaction is incorporated during hydrogel production, physical stimulation or chemical stimulation applied in conventional hydrogel production methods requires a sophisticated process and can affect the activity and structure of particles in the hydrogel. On the other hand, a hydrogel using an aqueous-two phase system and a method for producing same provided by the present invention can simultaneously achieve hydrogel formation and the encapsulation of desired nanoparticles in the hydrogel. The present invention has succeeded in simply concentrating desired nanoparticles in a hydrogel with a high yield. In addition, the present invention relates to a hydrogel using an aqueous-two phase system and a method for producing same, wherein concentration and hydrogel formation are simultaneously performed, and thus the time for producing the hydrogel is reduced and the cost is significantly reduced.

ZWITTERIONIC PHOSPHOLIPID COMPOUND AND LIPID NANOPARTICLE CONTAINING THE SAME

Resumen de: WO2025084317A1

The purpose of the invention described herein is to provide a compound having a novel chemical structure that is usable for lipid nanoparticles. Disclosed are a compound represented by formula (I) (in the formula, R1 and R2 are each independently a C10-24 chain hydrocarbon group, R3 is a C1-22 chain hydrocarbon group) and lipid nanoparticles containing the compound.

SYNTHESIS, FABRICATION AND USE OF NANOPARTICLES WITH ATOMIC VACANCIES FOR MITOCHONDRIAL THERAPIES

Resumen de: WO2025085275A1

The present disclosure provides compositions and methods for increasing mitochondrial function or decreasing cellular oxidative stress. The present disclosure further provides nanomaterial structures comprising high atomic vacancy concentrations. Aspects of the disclosure further relate to methods for treating diseases or disorders associated with decreased mitochondrial function or increased cellular oxidative stress.

ZEOLITE COMPOSITIONS WITH OSTEOINDUCTIVE AND ANTI-INFLAMMATORY THERAPEUTIC EFFECTS AND METHODS OF USE THEREOF

Resumen de: WO2025085507A2

The present invention provides multi-functional (e.g., repelling biofilms, promoting formation of minerals, and having anti-infection properties) compositions and methods of use thereof. In various embodiments, the present invention also provides method for promoting bone growth, promoting cell adhesion, promoting cell expression, promoting anti-infection effect (e.g., promoting anti-bacterial effect, promoting anti-fungal effect, promoting anti-viral effect, etc.), promoting anti-inflammatory effect, preventing or treating diseases or disorders, or any combination thereof in a subject in need thereof.

ARMORED IMMUNORESPONSIVE CELLS TARGETING DLL3 AND USES THEREOF

Resumen de: WO2025085796A1

The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target DLL3 and cells comprising such DLL3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the DLL3-targeted antigen-recognizing receptors for treatment.

CO-ASSEMBLED PEPTIDE GRANULES FOR RNA-GUIDED NUCLEASE DELIVERY

Resumen de: WO2025085865A1

Provided herein are co-assembling peptides which may form granules under stimulating conditions. Also provided herein are granules comprising RNA-guided nucleases which are capable of modifying DNA, for example, in the presence of a guide RNA. Further provided herein are methods of making each of the co-assembling peptides and granules thereof.

DNA ENCODED NANOPARTICLES WITH CYTOKINE ADJUVANT AND METHOD OF USE THEREOF

Resumen de: WO2025085909A1

Disclosed herein are nanoparticle immunoadjuvant complexes and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating or preventing a disease or disorder associated with an antigen presented on n nanoparticle immunoadjuvant complex in a subject in need thereof, by administering the antigen presenting nanoparticle immunoadjuvant complex, or encoding nucleic acid molecules, to the subject.

POLYPHENOL NANOPARTICLES FOR RNA DELIVERY

Resumen de: WO2025085425A1

A non-cationic nanoparticle composition comprising an albumin-coated nanoparticle, which comprises a nucleic acid bound to a polyphenol; a method of preparation; and use thereof in the treatment or inhibition of onset of cancer and other diseases.

凍結乾燥組成物

Resumen de: CN119403545A

The present invention relates to a solid composition obtainable by freeze-drying an aqueous composition comprising rilpivirine or a pharmaceutically acceptable salt thereof and optionally a hyaluronidase. The invention also relates to a reconstituted aqueous composition obtainable by reconstituting a solid composition of the invention, a process for preparing a solid composition of the invention and the use of the reconstituted aqueous composition in the treatment or prevention of HIV infection in a subject.

ターゲット組織の大きさ又は体積の縮小用組成物、若しくはそれを含むキット

Resumen de: AU2023257167A1

The present invention provides a pharmaceutical composition for treating obesity, the composition including: one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or a genetic material coding for a protein derived from these viruses. Preferably, the pharmaceutical composition is a vaccine composition. The composition provides a reduction in target tissues, preferably tissues containing adipocytes, or an effect that leads to the death of adipocytes.

視力喪失を治療するためのｔＲＮＡ療法に関連する方法及び組成物

Resumen de: AU2023256601A1

Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.

IONIZABLE LIPIDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2025082973A1

The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.

PROTEIN-BASED NANOPARTICLES SUITABLE FOR TUMOUR TARGETING OF ANTI-CANCER DRUGS AND AGENTS

Resumen de: WO2025083423A1

The invention relates to a self-assembling conjugate molecule, the conjugate molecule comprising a hydrophobic polymer covalently bound to human serum albumin (HSA) only at residue Cys34; or a hydrophobic polymer covalently bound to a non-human serum albumin protein only at an equivalent residue to Cys34 of HSA; and associated compositions, uses and methods of treatment.

NANOPARTICLES AND FORMULATIONS THEREOF FOR DELIVERING THERAPEUTIC AGENTS THROUGHOUT THE CENTRAL NERVOUS SYSTEM

Resumen de: WO2025085881A1

Nanoemulsions (NEs) and nanocapsules (NCs), are disclosed that include nanoparticles that can readily diffuse/distribute throughout the nervous system and that can deliver a therapeutic agent thereto. Methods of making and using the same also are disclosed, especially for treating diseases and/or disorders in which delivery of a therapeutic agent to and/or throughout the nervous system are needed.

METHODS AND COMPOSITIONS FOR NUCLEIC CONSTRUCT DELIVERY

Resumen de: WO2025083617A1

The present disclosure includes a composition including a) one or more nucleic acid constructs, wherein the one or more nucleic acid constructs encode: at least one of Replicase 68 (Rep68) and Replicase 78 (Rep78); and at least one protein of viral origin having nucleic acid replication and/or transgene amplification promotion activity, and b) nucleic acid construct comprising a coding region encoding at least one gene of interest (GOI) and at least one inverted terminal repeat (ITR) sequence on each side of the GOI, and methods of making and using the composition.

2-METHYL-3-PHYTYL-1,4-NAPHTHOQUINONE FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES WITH DYSFUNCTION OF VASCULAR ENDOTHELIUM

Resumen de: WO2025084940A1

The invention relate to a compound of the general formula presented in the description of the invention for use in the treatment or prevention of diseases associated with vascular endothelial dysfunction, wherein it is provided in nanocapsules having a diameter of no more than 1 pm, containing a lipophilic core and a hydrophilic shell, wherein the nanocapsules are intended for oral administration.

METHODS AND COMPOSITIONS COMPRISING TOBACCO MILD GREEN MOSAIC VIRUS (TMGMV)

Resumen de: WO2023244803A1

This application relates in part to nanoparticles comprising a tobamovirus and nanoparticles comprising a tobamovirus and beta-cyclodextrin (β-CD or BCD). This application also relates in part to nanoparticles comprising tobamovirus and one or more active ingredients (AIs) that are non-covalently conjugated to the tobamovirus. The application also provides methods of making and methods of using such nanoparticles as well as compositions comprising the disclosed nanoparticles.

NANOMATERIALS COMPRISING TRIOLS

Resumen de: MX2025000643A

The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

CAR-EXPRESSING PLURIPOTENT STEM CELL-DERIVED NEUTROPHILS LOADED WITH DRUG NANOPARTICLES AND USES THEREOF

Resumen de: AU2023290273A1

Chimeric antigen receptor (CAR)-expressing neutrophils loaded with nanoparticles comprising a drug; and a method of treating cancer or other disorders in a subject comprising administering to the subject a therapeutically effective amount of the CAR-expressing neutrophils.

LIPID NANOPARTICLES (LNPS)-BASED OCULAR DELIVERY

Resumen de: AU2023290692A1

Provided herein include compositions, methods and systems for delivery of CRISPR/Cas-mediated gene editing systems using lipid nanoparticles (LNP) to trabecular meshwork cells. Methods, compositions and systems for treating glaucoma are also provided herein, which involve reducing the expression of myocilin (

PERIPHERALIZATION OF CENTRALLY-ACTING CANNABINOID-1 RECEPTOR ANTAGONISTS BY NANOPARTICLES FOR THE TREATMENT METABOLIC RELATED CONDITIONS

Resumen de: WO2023242843A1

The technology generally concerns selective modulation of only a peripheral CB 1R by using a CB 1R antagonist contained in a peripherally restricted delivery system.

TARGETED NANOMEDICINE FOR TREATING FIBROTIC LUNG DISORDERS

Resumen de: WO2023245176A1

This disclosure relates to compositions and methods for treating lung disorders, including, for example, pulmonary fibrosis, and other fibrotic disorders. Thioredoxin domain-containing 5 (TXNDC5) is significantly increased in fibrotic lungs from human PF patients. Therefore, a targeted nanoparticle comprising an inhibitor of TXNDC5 was developed, which may have potential to treat pulmonary fibrosis.

生体直交型組成物

Resumen de: CN117567535A

The present application relates to bio-orthogonal compositions. The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing these compositions and methods of using these compositions.

イオン化可能なアミン脂質及び脂質ナノ粒子

Resumen de: PH12021500045A1

The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

LONG-LASTING ANAESTHETIC FORMULATION

Resumen de: AU2023290551A1

The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and/or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.

TARGETED NANOMEDICINE FOR TREATING LUNG DISORDERS

Resumen de: WO2023245177A2

This disclosure relates to compositions and methods for treating lung disorders, including, for example, Acute Respiratory Distress Syndrome (ARDS), Ventilator-Induced Lung Injury (VILI), Acute lung injury (ALI), and other acute and chronic lung disorders.

METHODS AND COMPOSITIONS OF QUATERNARY IMMUNOMODULATORY NANOPARTICLES FOR MEDICAL APPLICATIONS AND IMMUNOTHERAPY

Resumen de: AU2023295550A1

The present disclosure provides a method of enhancing an immune response in a subject in need thereof, including administering an effective amount of an antigen with an immune modulator to the subject, wherein the immune modulator is a quaternary immunomodulatory nanoparticle (QIN). The present disclosure also provides the use of the QIN in the manufacture of a chimeric nanoparticle, a pharmaceutical composition and a medicament for treating a subject suffering from a cancer or virus infection.

間葉系幹細胞のエクソソーム、滑膜間葉系幹細胞、及び足場の併用による変形性関節症の治療方法

Resumen de: MX2021009485A

Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device; covering articular cartilage in an affected joint with a scaffold; and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells.

一种靶向治疗黄褐斑的siRNA脂质纳米颗粒及其制备方法和应用

Resumen de: CN119857085A

本发明提供了一种靶向治疗黄褐斑的siRNA脂质纳米颗粒及其制备方法和应用，属于生物医药技术领域。本发明提供了一种治疗黄褐斑的LNP‑siRNAs，包括靶向抑制黑色素形成关键分子的siRNAs。本发明筛选出有效的siRNA序列，在细胞中进行了验证，而后将有明显抑制作用的siRNAs包装成LNP‑siRNAs，评估LNP‑siRNAs的包装质量，以及将LNP‑siRNAs用于细胞和动物，评估其对黑色素的抑制效应。本发明包装成的LNP‑siRNAs后用于黑色素细胞和动物皮肤，发现其能有效抑制黑色素的形成，可作为筛选并制作临床治疗黄褐斑的潜在药物。

一种石萝藦提取物纳米粒组合物、制备方法及应用

Resumen de: CN119857120A

本发明提供了一种石萝藦提取物纳米粒、制备方法及应用，属于生物医药技术领域。纳米粒由囊心填充物、载体材料、表面活性剂、乳化剂和水组成；所述囊心填充物为石萝藦提取物；所述载体材料为聚乙二醇‑聚乳酸。配比如下：L‑LA、PEG和辛酸亚锡的摩尔比为100:1:1制得聚乙二醇‑聚乳酸(PEG‑PLLA)，PEG‑PLLA与PC重量比为1:3制得PC@PEG‑PLLA纳米颗粒。PC@PEG‑PLLA NPs的平均粒径为(113.1±2.5)nm，PDI为(0.173±0.020)，电势为(‑46.7±1.9)mV，同时具有良好的稳定性。作为治疗自身免疫性肝炎(AIH)的药物具有较高的价值。

编码流感病毒抗原的自扩增RNA

Resumen de: MX2025000397A

Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.

一种治疗肝细胞癌的核酸药物及其制备方法和应用

Resumen de: CN119857150A

本发明提供了一种治疗肝细胞癌的核酸药物制剂及其制备方法和应用，属于核酸药物技术领域。本发明提供了一种核酸递送载体，包括中性胞苷脂材DNCA、胱氨酸骨架阳离子脂材CLD和辅助脂材1,2‑二硬脂酰基‑sn‑甘油‑3‑磷酸乙醇胺‑聚乙二醇DSPE‑PEG按特定比例复配得到。本发明还提供了一种治疗肝细胞癌的核酸药物，包括核酸递送载体、包裹在所述核酸递送载体内靶向IGF1RmRNA的siRNA和细胞转染液。所述核酸药物可高效靶向小鼠肝细胞皮下瘤部位，显著抑制肿瘤生长，且无肝肾毒性。本发明技术方案为抗该肝细胞癌的siRNA药物在临床的广泛应用奠定了基础。

ＣＩＤＥＢを標的にするｓｉＲＮＡを用いて肝疾患を処置するための組成物および方法

Resumen de: MX2024012237A

Disclosed herein are compositions comprising siRNAs capable of downregulating Cell Death-Inducing DFF45-like Effector Protein B (<i>CIDEB</i>) gene expression or a variant thereof. Also disclosed herein are methods of using such compositions in the treatment of a liver disease or injury, such as fatty liver disease (FLD), non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

細胞変換

Resumen de: WO2023199036A1

The present application relates to a nucleic acid molecule comprising a promoter operably linked to a nucleic acid sequence encoding Myocyte Enhancer Factor 2C (MEF2C), or a functional variant thereof, wherein the promoter is for expression of MEF2C in macroglia. Also provided are vectors, compositions, products, methods, cells, medical uses and methods of treatment.

ｍＲＮＡ送達方法およびその組成物

Resumen de: AU2023244571A1

The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from 30 mol% to 70 mol%; (iii) a ionizable, cationic lipid content of from 5 mol% to 50 mol%; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol% to 5 mol. Further provided is a lipid nanoparticle comprising encapsulated mRNA and 20 to 70 mol% of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. Further provided are methods of administration of such lipid nanoparticles.

肝臓へのプラスミドＤＮＡデリバリーのための脂質ナノ粒子の組成物およびその調製方法

Resumen de: WO2023192503A1

Lipid nanoparticle formulations with cell type specific transfection activity and capable of producing Th1 and/or Th2 response in vivo and their use for plasmid DNA or mRNA delivery is disclosed.

2-Methyl-3-phytyl-1,4-naphthoquinone for use in the treatment or prevention of diseases associated with vascular endothelial dysfunction

Resumen de: WO2025084940A1

The invention relate to a compound of the general formula presented in the description of the invention for use in the treatment or prevention of diseases associated with vascular endothelial dysfunction, wherein it is provided in nanocapsules having a diameter of no more than 1 pm, containing a lipophilic core and a hydrophilic shell, wherein the nanocapsules are intended for oral administration.

肿瘤微环境响应型级联生成活性氧的纳米平台及其制备方法、应用

Resumen de: CN119857110A

本发明提供一种肿瘤微环境响应型级联生成活性氧的纳米平台及其制备方法，该纳米平台包括FeOOH纳米纺锤体，所述FeOOH纳米纺锤体的外层包覆有四硫键掺入的树枝状介孔有机硅纳米粒子(DMOS NPs)，形成纳米颗粒DMOS@FeOOH。本发明的纳米平台能够在肿瘤组织中通过级联反应高效生成活性氧(ROS)，并实现对肿瘤细胞的选择性杀伤，具有较高的特异性、良好的治疗效果和较低的对正常组织的副作用，是一种具有广阔应用前景的肿瘤治疗策略。

高ステロール含有脂質ナノ粒子

Nº publicación: JP2025512763A 22/04/2025

Solicitante:

ナノベーション・セラピューティクス・インコーポレイテッド

Resumen de: CN118922178A

The present disclosure provides a lipid nanoparticle comprising: a nucleic acid load molecule; sterols or derivatives thereof present in high levels; a neutral lipid; lipid can be ionized; and a hydrophilic polymer-lipid conjugate present in a content of between 0.5 and 3 mol%, wherein each mol% content is relative to the total lipid present in the lipid nanoparticles.